From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of December 15–21, 2025.
Czech Republic (Ministry of Health) (N/A): Czechia approves regulations enabling medical psilocybin access from 2026
The Czech Republic confirmed the clinical conditions for its medical psilocybin framework, with a government decree setting out that certified psychiatrists with psychedelic training may administer synthetic psilocybin to patients with cancer-related depression, serious non-psychotic depression, or life-threatening deteriorations in mental state. Rollout will initially be limited to a few dozen patients annually, mainly in Prague and Brno, making Czechia the first EU member state with a full legal framework for medical psilocybin.
Source: forbes.com
Cybin Inc. (CYBN): Cybin to rebrand as Helus Pharma and move U.S. listing to Nasdaq
Cybin announced it would voluntarily transfer its U.S. listing from NYSE American to the Nasdaq Global Market and do business as Helus Pharma, trading under the new ticker HELP instead of CYBN. The company said its shares would stop trading on NYSE American at the close on January 2, 2026 and begin on Nasdaq on January 5, framing the move as aligning the late-stage developer with a larger biopharma peer group to boost investor visibility.
Source: tipranks.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.